|
Torrent Pharmaceuticals Limited (torntpharm.ns) Valoración de DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Torrent Pharmaceuticals Limited (TORNTPHARM.NS) Bundle
¡Explore el futuro financiero de Torrent Pharmaceuticals Limited (Torntpharmns) con nuestra calculadora DCF fácil de usar! Ingrese sus suposiciones para el crecimiento, los márgenes y los costos para determinar el valor intrínseco de Torrent Pharmaceuticals Limited (Torntpharmns) y mejorar su estrategia de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77,800.1 | 78,862.3 | 84,188.0 | 94,640.0 | 106,054.3 | 114,696.2 | 124,042.3 | 134,150.0 | 145,081.3 | 156,903.3 |
| Revenue Growth, % | 0 | 1.37 | 6.75 | 12.42 | 12.06 | 8.15 | 8.15 | 8.15 | 8.15 | 8.15 |
| EBITDA | 22,887.9 | 25,365.1 | 21,429.0 | 28,826.3 | 35,009.7 | 34,525.0 | 37,338.3 | 40,380.9 | 43,671.3 | 47,229.9 |
| EBITDA, % | 29.42 | 32.16 | 25.45 | 30.46 | 33.01 | 30.1 | 30.1 | 30.1 | 30.1 | 30.1 |
| Depreciation | 6,515.1 | 6,573.1 | 6,619.3 | 7,020.3 | 7,953.0 | 9,058.4 | 9,796.5 | 10,594.8 | 11,458.1 | 12,391.7 |
| Depreciation, % | 8.37 | 8.33 | 7.86 | 7.42 | 7.5 | 7.9 | 7.9 | 7.9 | 7.9 | 7.9 |
| EBIT | 16,372.8 | 18,792.0 | 14,809.7 | 21,806.0 | 27,056.7 | 25,466.7 | 27,541.8 | 29,786.1 | 32,213.2 | 34,838.2 |
| EBIT, % | 21.04 | 23.83 | 17.59 | 23.04 | 25.51 | 22.2 | 22.2 | 22.2 | 22.2 | 22.2 |
| Total Cash | 6,623.2 | 7,380.1 | 5,829.5 | 8,350.0 | 10,040.0 | 9,883.5 | 10,688.8 | 11,559.8 | 12,501.8 | 13,520.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 19,957.2 | 18,945.4 | 19,206.9 | 22,370.8 | 18,443.0 | 26,040.1 | 28,162.0 | 30,456.7 | 32,938.5 | 35,622.6 |
| Account Receivables, % | 25.65 | 24.02 | 22.81 | 23.64 | 17.39 | 22.7 | 22.7 | 22.7 | 22.7 | 22.7 |
| Inventories | 21,482.2 | 26,812.0 | 24,623.2 | 22,300.0 | 22,790.7 | 31,177.0 | 33,717.4 | 36,464.9 | 39,436.3 | 42,649.8 |
| Inventories, % | 27.61 | 34 | 29.25 | 23.56 | 21.49 | 27.18 | 27.18 | 27.18 | 27.18 | 27.18 |
| Accounts Payable | 20,488.1 | 20,668.1 | 16,744.4 | 16,788.0 | 20,893.2 | 25,203.5 | 27,257.2 | 29,478.3 | 31,880.4 | 34,478.2 |
| Accounts Payable, % | 26.33 | 26.21 | 19.89 | 17.74 | 19.7 | 21.97 | 21.97 | 21.97 | 21.97 | 21.97 |
| Capital Expenditure | -4,067.8 | -3,351.5 | -2,025.7 | -5,740.0 | -4,327.8 | -5,053.6 | -5,465.4 | -5,910.7 | -6,392.4 | -6,913.3 |
| Capital Expenditure, % | -5.23 | -4.25 | -2.41 | -6.07 | -4.08 | -4.41 | -4.41 | -4.41 | -4.41 | -4.41 |
| Tax Rate, % | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 | 29.58 |
| EBITAT | 14,139.5 | 15,413.7 | 9,388.8 | 14,701.4 | 19,053.6 | 18,825.9 | 20,360.0 | 22,019.0 | 23,813.2 | 25,753.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4,364.5 | 14,497.3 | 11,986.0 | 15,184.6 | 30,221.1 | 11,157.7 | 22,082.4 | 23,881.8 | 25,827.8 | 27,932.4 |
| WACC, % | 5.79 | 5.78 | 5.72 | 5.73 | 5.74 | 5.75 | 5.75 | 5.75 | 5.75 | 5.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 92,255.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 29,050 | |||||||||
| Terminal Value | 1,656,913 | |||||||||
| Present Terminal Value | 1,252,654 | |||||||||
| Enterprise Value | 1,344,909 | |||||||||
| Net Debt | 31,868 | |||||||||
| Equity Value | 1,313,041 | |||||||||
| Diluted Shares Outstanding, MM | 338 | |||||||||
| Equity Value Per Share | 3,879.62 |
What You Will Receive
- Customizable Excel Template: A comprehensive Excel-based DCF Calculator featuring pre-filled financial data for TORNTPHARMNS.
- Accurate Data: Access to historical performance metrics and forward-looking projections (highlighted in the yellow cells).
- Adaptable Forecasting: Modify key assumptions such as revenue growth, EBITDA margin, and WACC easily.
- Instant Calculations: Instantly observe how your changes affect the valuation of Torrent Pharmaceuticals.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Interface: Organized for simplicity and ease of navigation, complete with step-by-step guidance.
Key Features
- Pre-Loaded Data: Torrent Pharmaceuticals Limited's historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: Observe the intrinsic value of Torrent Pharmaceuticals Limited recalculating in real time.
- Clear Visual Outputs: Dashboard charts showcase valuation results and essential metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.
How It Operates
- Download: Obtain the preformatted Excel file containing Torrent Pharmaceuticals Limited's (TORNTPHARMNS) financial data.
- Customize: Modify projections, including revenue growth rates, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and instantly compare the results.
- Make Decisions: Utilize the valuation insights to inform your investment approach.
Why Opt for This Calculator?
- Precision: Reliable Torrent Pharmaceuticals (TORNTPHARMNS) financials guarantee data integrity.
- Versatility: Crafted to allow users to experiment and adjust inputs effortlessly.
- Efficiency: Avoid the complexity of constructing a DCF model from the ground up.
- Expert-Level: Designed with the accuracy and usability expected by finance professionals.
- Accessible: Simple to navigate, making it suitable for users without extensive financial modeling skills.
Who Should Utilize This Product?
- Investors: Evaluate Torrent Pharmaceuticals Limited’s (TORNTPHARMNS) fair value with precision prior to investment choices.
- CFOs: Utilize an advanced DCF model for enhanced financial reporting and analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Understand the financial modeling practices adopted by leading pharmaceutical companies.
- Educators: Employ it as a resource to illustrate valuation techniques in the classroom.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Torrent Pharmaceuticals Limited (TORNTPHARMNS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the calculation of Weighted Average Cost of Capital (WACC), featuring key parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that illustrate the intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Contains profitability, leverage, and efficiency ratios specific to Torrent Pharmaceuticals Limited (TORNTPHARMNS).
- Dashboard and Charts: Visual representation of valuation outputs and assumptions for straightforward result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.